Literature DB >> 30760859

Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies.

Wedad M Hanna1, Carlos Parra-Herran2, Fang-I Lu2, Elzbieta Slodkowska2, Eileen Rakovitch2, Sharon Nofech-Mozes2.   

Abstract

Ductal carcinoma in situ (DCIS) is a neoplastic proliferation of mammary ductal epithelial cells confined to the ductal-lobular system, and a non-obligate precursor of invasive disease. While there has been a significant increase in the diagnosis of DCIS in recent years due to uptake of mammography screening, there has been little change in the rate of invasive recurrence, indicating that a large proportion of patients diagnosed with DCIS will never develop invasive disease. The main issue for clinicians is how to reliably predict the prognosis of DCIS in order to individualize patient treatment, especially as treatment ranges from surveillance only, breast-conserving surgery only, to breast-conserving surgery plus radiotherapy and/or hormonal therapy, and mastectomy with or without radiotherapy. We conducted a semi-structured literature review to address the above issues relating to "pure" DCIS. Here we discuss the pathology of DCIS, risk factors for recurrence, biomarkers and molecular signatures, and disease management. Potential mechanisms of progression from DCIS to invasive cancer and problems faced by clinicians and pathologists in diagnosing and treating this disease are also discussed. Despite the tremendous research efforts to identify accurate risk stratification predictors of invasive recurrence and response to radiotherapy and endocrine therapy, to date there is no simple, well-validated marker or group of variables for risk estimation, particularly in the setting of adjuvant treatment after breast-conserving surgery. Thus, the standard of care to date remains breast-conserving surgery plus radiotherapy, with or without hormonal therapy. Emerging tools, such as pathologic or biologic markers, may soon change such practice. Our review also includes recent advances towards innovative treatment strategies, including targeted therapies, immune modulators, and vaccines.

Entities:  

Mesh:

Year:  2019        PMID: 30760859     DOI: 10.1038/s41379-019-0204-1

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  10 in total

1.  Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.

Authors:  Helga Bergholtz; Tonje G Lien; David M Swanson; Arnoldo Frigessi; Maria Grazia Daidone; Jörg Tost; Fredrik Wärnberg; Therese Sørlie
Journal:  NPJ Breast Cancer       Date:  2020-06-17

Review 2.  Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy.

Authors:  Stuart J Schnitt
Journal:  Mod Pathol       Date:  2020-09-09       Impact factor: 7.842

Review 3.  Immune microenvironment in different molecular subtypes of ductal breast carcinoma.

Authors:  Mona Sadeghalvad; Hamid-Reza Mohammadi-Motlagh; Nima Rezaei
Journal:  Breast Cancer Res Treat       Date:  2020-10-03       Impact factor: 4.872

4.  Palpable Lumps after Mastectomy: Radiologic-Pathologic Review of Benign and Malignant Masses.

Authors:  Rend Al-Khalili; Ali Alzeer; Giang-Kimthi Nguyen; Erin P Crane; Judy H Song; Janice L Jeon; Michael Nellamattathil; Erini V Makariou; Victoria L Mango
Journal:  Radiographics       Date:  2021-05-14       Impact factor: 6.312

5.  Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions.

Authors:  Helga Bergholtz; Tonje G Lien; David M Swanson; Arnoldo Frigessi; Maria Grazia Daidone; Jörg Tost; Fredrik Wärnberg; Therese Sørlie
Journal:  NPJ Breast Cancer       Date:  2020-06-17

6.  Pure Ductal Carcinoma In Situ of the Breast: Analysis of 270 Consecutive Patients Treated in a 9-Year Period.

Authors:  Corrado Chiappa; Alice Bonetti; Giulio Jad Jaber; Valentina De Berardinis; Veronica Bianchi; Francesca Rovera
Journal:  Cancers (Basel)       Date:  2021-01-23       Impact factor: 6.639

7.  Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.

Authors:  Matthew G Davey; Colm O'Flaherty; Eoin F Cleere; Aoife Nohilly; James Phelan; Evan Ronane; Aoife J Lowery; Michael J Kerin
Journal:  BJS Open       Date:  2022-03-08

8.  A Novel Nomogram for Predicting Prognosis and Tailoring Local Therapy Decision for Ductal Carcinoma In Situ after Breast Conserving Surgery.

Authors:  Feifei Xu; Lu Cao; Cheng Xu; Gang Cai; Rong Cai; Weixiang Qi; Shubei Wang; Kunwei Shen; Weimin Chai; Jiayi Chen
Journal:  J Clin Med       Date:  2022-09-01       Impact factor: 4.964

Review 9.  Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer.

Authors:  Jarupa Soongsathitanon; Pranisa Jamjuntra; Nuttavut Sumransub; Supaporn Yangngam; Marjorie De la Fuente; Glauben Landskron; Peti Thuwajit; Marcela A Hermoso; Chanitra Thuwajit
Journal:  J Immunol Res       Date:  2021-07-13       Impact factor: 4.818

Review 10.  Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors.

Authors:  Lucia Salvatorelli; Lidia Puzzo; Giada Maria Vecchio; Rosario Caltabiano; Valentina Virzì; Gaetano Magro
Journal:  Cancers (Basel)       Date:  2020-03-06       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.